A Phase 2a Study of BMS-790052 and BMS-650032 in Combination Therapy With Japanese Subjects With Genotype 1 Chronic Hepatitis C (HCV) Virus Infection.

Trial Profile

A Phase 2a Study of BMS-790052 and BMS-650032 in Combination Therapy With Japanese Subjects With Genotype 1 Chronic Hepatitis C (HCV) Virus Infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2016

At a glance

  • Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Apr 2012 Results have been presented at the the 47th annual meeting of the European Association for the Study of the Liver according to a Bristol-Myers Squibb media release.
    • 09 Nov 2011 Results from a sentinel cohort of 10 patients were presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
    • 30 Aug 2011 Planned end date changed from 1 Oct 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top